Chemo-sensitization of CD133+ cancer stem cell enhances the effect of mesenchymal stem cell expressing TRAIL in non-small cell lung cancer cell lines
Pre-clinical studies have demonstrated the efficacy of mesenchymal stem cells (MSCs) expressing tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) or MSC-TRAIL against several tumors. However, due to the existence of cancer stem cells (CSCs), some tumors, including non-small cell...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Published: |
Multidisciplinary Digital Publishing Institute
2021
|
| _version_ | 1825937704432435200 |
|---|---|
| author | Fakiruddin, Kamal Shaik Moon, Nian Lim Nordin, Norshariza Rosli, Rozita Abdullah, Syahril |
| author_facet | Fakiruddin, Kamal Shaik Moon, Nian Lim Nordin, Norshariza Rosli, Rozita Abdullah, Syahril |
| author_sort | Fakiruddin, Kamal Shaik |
| collection | UPM |
| description | Pre-clinical studies have demonstrated the efficacy of mesenchymal stem cells (MSCs) expressing tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) or MSC-TRAIL against several tumors. However, due to the existence of cancer stem cells (CSCs), some tumors, including non-small cell lung cancer (NSCLC), exhibit TRAIL resistance. This study was designed to evaluate the capacity of using first-line chemotherapies including cisplatin, 5-fluorouracil (5-FU) and vinorelbine to act as a chemo-sensitizer on CD133+ (prominin-1 positive) CSCs derived from NSCLC cell lines (A549, H460 and H2170) for the purpose of MSC-TRAIL-induced inhibition. We showed that MSC-TRAIL was resistant to all three chemotherapies compared to the NSCLC cell lines, suggesting that the chemotherapies had little effect on MSC-TRAIL viability. Pre-treatment using either cisplatin or 5-FU, but not with vinorelbine, was able to increase the efficacy of MSC-TRAIL to kill the TRAIL-resistant A549-derived CSCs. The study also demonstrated that both 5-FU and vinorelbine were an effective chemo-sensitizer, used to increase the anti-tumor effect of MSC-TRAIL against H460- and H2170-derived CSCs. Furthermore, pre-treatment using cisplatin was noted to enhance the effect of MSC-TRAIL in H460-derived CSCs; however, this effect was not detected in the H2170-derived CSCs. These findings suggest that a pre-treatment using certain chemotherapies in NSCLC could enhance the anti-tumor effect of MSC-TRAIL to target the CSCs, and therefore the combination of chemotherapies and MSC-TRAIL may serve as a novel approach for the treatment of NSCLC. |
| first_indexed | 2024-03-06T11:03:33Z |
| format | Article |
| id | upm.eprints-96383 |
| institution | Universiti Putra Malaysia |
| last_indexed | 2024-03-06T11:03:33Z |
| publishDate | 2021 |
| publisher | Multidisciplinary Digital Publishing Institute |
| record_format | dspace |
| spelling | upm.eprints-963832023-01-26T07:39:33Z http://psasir.upm.edu.my/id/eprint/96383/ Chemo-sensitization of CD133+ cancer stem cell enhances the effect of mesenchymal stem cell expressing TRAIL in non-small cell lung cancer cell lines Fakiruddin, Kamal Shaik Moon, Nian Lim Nordin, Norshariza Rosli, Rozita Abdullah, Syahril Pre-clinical studies have demonstrated the efficacy of mesenchymal stem cells (MSCs) expressing tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) or MSC-TRAIL against several tumors. However, due to the existence of cancer stem cells (CSCs), some tumors, including non-small cell lung cancer (NSCLC), exhibit TRAIL resistance. This study was designed to evaluate the capacity of using first-line chemotherapies including cisplatin, 5-fluorouracil (5-FU) and vinorelbine to act as a chemo-sensitizer on CD133+ (prominin-1 positive) CSCs derived from NSCLC cell lines (A549, H460 and H2170) for the purpose of MSC-TRAIL-induced inhibition. We showed that MSC-TRAIL was resistant to all three chemotherapies compared to the NSCLC cell lines, suggesting that the chemotherapies had little effect on MSC-TRAIL viability. Pre-treatment using either cisplatin or 5-FU, but not with vinorelbine, was able to increase the efficacy of MSC-TRAIL to kill the TRAIL-resistant A549-derived CSCs. The study also demonstrated that both 5-FU and vinorelbine were an effective chemo-sensitizer, used to increase the anti-tumor effect of MSC-TRAIL against H460- and H2170-derived CSCs. Furthermore, pre-treatment using cisplatin was noted to enhance the effect of MSC-TRAIL in H460-derived CSCs; however, this effect was not detected in the H2170-derived CSCs. These findings suggest that a pre-treatment using certain chemotherapies in NSCLC could enhance the anti-tumor effect of MSC-TRAIL to target the CSCs, and therefore the combination of chemotherapies and MSC-TRAIL may serve as a novel approach for the treatment of NSCLC. Multidisciplinary Digital Publishing Institute 2021 Article PeerReviewed Fakiruddin, Kamal Shaik and Moon, Nian Lim and Nordin, Norshariza and Rosli, Rozita and Abdullah, Syahril (2021) Chemo-sensitization of CD133+ cancer stem cell enhances the effect of mesenchymal stem cell expressing TRAIL in non-small cell lung cancer cell lines. Biology-Basel, 10 (11). 1103 - 1107. ISSN 2079-7737 https://www.mdpi.com/2079-7737/10/11/1103 10.3390/biology10111103 |
| spellingShingle | Fakiruddin, Kamal Shaik Moon, Nian Lim Nordin, Norshariza Rosli, Rozita Abdullah, Syahril Chemo-sensitization of CD133+ cancer stem cell enhances the effect of mesenchymal stem cell expressing TRAIL in non-small cell lung cancer cell lines |
| title | Chemo-sensitization of CD133+ cancer stem cell enhances the effect of mesenchymal stem cell expressing TRAIL in non-small cell lung cancer cell lines |
| title_full | Chemo-sensitization of CD133+ cancer stem cell enhances the effect of mesenchymal stem cell expressing TRAIL in non-small cell lung cancer cell lines |
| title_fullStr | Chemo-sensitization of CD133+ cancer stem cell enhances the effect of mesenchymal stem cell expressing TRAIL in non-small cell lung cancer cell lines |
| title_full_unstemmed | Chemo-sensitization of CD133+ cancer stem cell enhances the effect of mesenchymal stem cell expressing TRAIL in non-small cell lung cancer cell lines |
| title_short | Chemo-sensitization of CD133+ cancer stem cell enhances the effect of mesenchymal stem cell expressing TRAIL in non-small cell lung cancer cell lines |
| title_sort | chemo sensitization of cd133 cancer stem cell enhances the effect of mesenchymal stem cell expressing trail in non small cell lung cancer cell lines |
| work_keys_str_mv | AT fakiruddinkamalshaik chemosensitizationofcd133cancerstemcellenhancestheeffectofmesenchymalstemcellexpressingtrailinnonsmallcelllungcancercelllines AT moonnianlim chemosensitizationofcd133cancerstemcellenhancestheeffectofmesenchymalstemcellexpressingtrailinnonsmallcelllungcancercelllines AT nordinnorshariza chemosensitizationofcd133cancerstemcellenhancestheeffectofmesenchymalstemcellexpressingtrailinnonsmallcelllungcancercelllines AT roslirozita chemosensitizationofcd133cancerstemcellenhancestheeffectofmesenchymalstemcellexpressingtrailinnonsmallcelllungcancercelllines AT abdullahsyahril chemosensitizationofcd133cancerstemcellenhancestheeffectofmesenchymalstemcellexpressingtrailinnonsmallcelllungcancercelllines |